Ebola Bundibugyo: ECDC data rise to 6,342 confirmed cases; CDC reports five targets not met

This morning this newspaper reported on the WHO’s emergency guidance on the potential use of the Ervebo vaccine. This afternoon’s development concerns the figures from the same outbreak and the assessment of the response on the ground, coming from two different institutional sources.

The European figures

According to the ECDC update of September 3, built on data from the Congolese national public health institute updated to September 2, the Democratic Republic of Congo has reported 6,342 confirmed cases of Bundibugyo virus disease and 3,072 related deaths. Compared with the previous report, there are 92 new confirmed cases and 33 new deaths.

The 92 new cases are distributed among Ituri (60), North Kivu (25), Haut Uele (5) and Tshopo (2). There are 770 patients admitted in isolation; recoveries among those positive for the Bundibugyo virus number 1,475. 86.5% of identified contacts are under surveillance in the affected provinces. Ituri remains the most affected province, with 5,164 cases and 2,342 deaths distributed across 28 of the 36 health zones.

For residents of the European Union and the European Economic Area, the ECDC rates the probability of infection as very low. The next update is announced for September 7. A situational overview is also published by the US Centers for Disease Control and Prevention.

The response assessment

A note published in the Morbidity and Mortality Weekly Report by the CDC captures the situation at an earlier date — August 21 — with 5,458 confirmed cases and 2,606 confirmed deaths, equal to 48%. The document describes the current outbreak as the second-largest ever recorded for Ebola and describes the pace of the increase as unprecedented, with approximately 5,000 cases in 100 days. The cases affect six of the 26 Congolese provinces and 57 of the 151 health zones in the affected provinces; Ituri accounts for 84% of reported cases.

The central point of the note concerns the five critical indicators of the public health response — alert, contact tracing, laboratory capacity, isolation, safe burials: none of the related targets has been met. The outbreak was declared by the Congolese Ministry of Public Health on May 15, 2026.

Limitations to note: this is surveillance data in an emergency context, not a controlled study; the reference dates of the sources cited in this piece differ and the totals are not comparable with one another; the MMWR note is a public health report based on available national data, and the count of confirmed cases does not coincide with actual cases.

The framework of the international response

The WHO declared the outbreak a Public Health Emergency of International Concern on May 16, 2026; Africa CDC classified it as a continental health security emergency. On May 28 the WHO indicated the antiviral remdesivir and the monoclonal antibodies MBP-134 and maftivimab for clinical trials; trials of remdesivir and MBP-134 began in Congo in July. A structural obstacle remains: existing treatments and vaccines were developed against the Ebola Zaire virus, not against Bundibugyo, which complicates the response. A WHO update indicated, as of August 12, 4,665 confirmed cases and 2,184 deaths, with a crude case fatality rate of 46.8% across 54 health zones in six provinces.

What we don’t know

The trials launched in July are ongoing experiments: no efficacy results appear in the available material, and none of the molecules mentioned is indicated as an available treatment. We don’t know why 13.5% of identified contacts are not under surveillance, nor what the gap is between reported cases and actual cases. The next verifiable data point is the ECDC update of September 7.